A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells

Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraiwa, Hiroshi, Sekine, Teruaki, Tobisu, Ken‐ichi, Kakizoe, Tadao, Koiso, Kenkichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1991
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://www.ncbi.nlm.nih.gov/pubmed/1906847
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x
Descripción
Sumario:Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with biotinylated monoclonal antibody. These monoclonal antibody‐conjugated LAK cells showed specifically enhanced killing activities against anti‐tumor antibody‐reactive cancer cells, and cold target cells specifically inhibited their activities.

Ejemplares similares